Status
Conditions
Treatments
About
Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.
Full description
Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. Because conventional endoscopy is invasive and costly, gastric cancer is currently not considered to be screenable at a population level. However, if one could find less invasive and cheaper tools that accurately detect gastric cancer in its early stages, it could make a significant difference. Accurate biomarkers could help identify patients with gastric cancer before it becomes incurable.
This study aims to develop a non-invasive test to detect gastric cancer early. It consists of four phases:
In summary, this study aims to develop a highly accurate and cost-effective blood test for detecting gastric cancer early. Success could lead to significant improvements in clinical practice by catching cancer when it is most treatable. By combining different genetic markers (cell-free microRNA and exosomal microRNA) for accuracy, this study has the potential to reduce gastric cancer deaths and could lead to new screening methods in the future.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
809 participants in 4 patient groups
Loading...
Central trial contact
Ajay Goel, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal